Tenaya Therapeutics, Inc. Quick Ratio
The quick ratio is a stricter test of whether a company can pay the bills due within a year, counting only assets that are already cash or close to it. It is cash, marketable securities and receivables divided by current liabilities, shown as a multiple, with both amounts in the table. It is the current ratio with inventory and other assets that take longer to turn into cash removed, so it is never higher than the current ratio. A company that does not report one of the inputs has no point for that date rather than an estimated one. Quarterly points use quarter-end balances; annual points use fiscal-year-end balances.
- Tenaya Therapeutics, Inc. quick ratio for the quarter ending 2026-06-30 was 4.12, a 27.17% decline year-over-year.
- Tenaya Therapeutics, Inc. quick ratio for the quarter ending 2026-03-31 was 5.45, a 12.46% decline year-over-year.
- Tenaya Therapeutics, Inc. quick ratio for the quarter ending 2025-12-31 was 6.51, a 69.35% increase year-over-year.
- Tenaya Therapeutics, Inc. quick ratio for the quarter ending 2025-09-30 was 4.26, a 13.22% decline year-over-year.
- Tenaya Therapeutics, Inc. quick ratio for fiscal 2025 was 6.51, a 69.35% increase from fiscal 2024.
- Tenaya Therapeutics, Inc. quick ratio for fiscal 2024 was 3.85, a 16.44% decline from fiscal 2023.
- Tenaya Therapeutics, Inc. quick ratio for fiscal 2023 was 4.6, a 40.16% decline from fiscal 2022.
- Tenaya Therapeutics, Inc. quick ratio for fiscal 2022 was 7.69, a 33.35% decline from fiscal 2021.
- Available history
- 2020-12-31 to 2026-06-30
- Data captured
Historical Quick Ratio
Annual Quick Ratio
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |